Filing Analysis
Abeona Therapeutics Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the press release containing these results.
📋 Key Facts
- The company issued a press release regarding financial results for the quarter ended June 30, 2026.
- The report was filed on August 13, 2026.
- Information provided under Item 2.02 is furnished rather than filed, limiting liability under Section 18 of the Exchange Act.
Abeona Therapeutics Inc. reported the results of its annual meeting of stockholders held on June 12, 2026. The company successfully elected directors, ratified its auditor, and increased shares for its equity incentive plan, though one amendment to the Certificate of Incorporation failed.
📋 Key Facts
- Keith A. Goldan and Bernhardt G. Zeiher, M.D. were elected as Class 1 directors until 2029.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The Second Amended and Restated 2023 Equity Incentive Plan was expanded, increasing reserved shares from 8,400,000 to 11,500,000.
- Executive compensation was approved via an advisory vote.
- A proposal to remove the advance notice provision for director nominations failed to meet the 66 2/3% affirmative vote threshold.
Abeona Therapeutics Inc. announced the immediate resignation of Michael Amoroso from its Board of Directors and the Nominating and Corporate Governance Committee on June 11, 2026.
📋 Key Facts
- Michael Amoroso resigned from the Board of Directors effective June 11, 2026.
- Mr. Amoroso also resigned from the Nominating and Corporate Governance Committee.
- The company stated the resignation was for personal reasons and not due to any disagreement regarding operations, policies, or practices.
Abeona Therapeutics Inc. filed an 8-K to furnish an updated investor presentation intended for use with investors and analysts.
📋 Key Facts
- The filing date is June 10, 2026.
- The company provided an updated 'Investor Presentation' as Exhibit 99.1.
- The information is furnished under Item 7.01 (Regulation FD), meaning it is not officially 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.
Abeona Therapeutics reports that it held a pre-Investigational New Drug (Pre-IND) meeting with the FDA on June 3, 2026, regarding its prostate cancer T-cell therapy, ABO-701. The company describes the meeting as constructive and maintains its target for an IND submission in 2027.
📋 Key Facts
- Pre-IND meeting occurred on June 3, 2026, regarding ABO-701 (T-cell therapy for prostate cancer).
- Official minutes from the FDA have not yet been received.
- The company is targeting an IND application submission in 2027.
- ABO-701 is described as a 'recently licensed radically novel engineered T-cell therapy'.
Abeona Therapeutics Inc. reported its financial results for the first quarter ended March 31, 2026. The filing includes a press release and an investor presentation detailing the company's quarterly performance and pipeline updates.
📋 Key Facts
- Financial results were reported for the fiscal quarter ended March 31, 2026.
- The company furnished a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2).
- The investor presentation is titled 'Q1 2026 Results and Pipeline Update'.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
Abeona Therapeutics expanded its Board of Directors from nine to ten members and appointed Keith A. Goldan as an independent Class 1 director. Mr. Goldan will also serve as the Chair of the Audit Committee and receive a compensation package consisting of cash and equity.
📋 Key Facts
- On April 1, 2026, the Board expanded from nine to ten members.
- Keith A. Goldan was appointed as a Class 1 director and Chair of the Audit Committee.
- Mr. Goldan will receive an annual cash fee of $50,000.
- A one-time sign-on equity grant of $150,000 in restricted stock was awarded with a one-year vesting period.
- The Board determined Mr. Goldan is an independent director under Nasdaq listing rules.
Abeona Therapeutics Inc. adopted its Third Amended and Restated Bylaws on March 16, 2026, introducing significant governance changes. The most notable updates include increasing the quorum requirement for stockholder meetings from one-third to 50% and enhancing disclosure requirements for stockholder-led director nominations and proposals.
🚩 Red Flags
- The increase in quorum to 50% and enhanced disclosure requirements for 'Stockholder Associated Persons' function as defensive measures that can impede shareholder activism or hostile takeovers.
- The elimination of the requirement to provide a stockholder list at meetings reduces transparency during the voting process.
📋 Key Facts
- The Board of Directors approved the Third Amended and Restated Bylaws effective March 16, 2026.
- Quorum for stockholder meetings was increased from one-third (33.3%) to 50% of shares entitled to vote.
- New disclosure requirements were added for stockholders and 'Stockholder Associated Persons' submitting proposals or nominations.
- Bylaws were updated to allow for virtual-only stockholder meetings via remote communication.
- Procedures were updated to comply with the SEC's universal proxy rules under Rule 14a-19.
- The requirement to make a stockholder list available for examination during meetings was eliminated, consistent with DGCL amendments.
Abeona Therapeutics Inc. reported its financial results for the fiscal year ended December 31, 2025, via a press release on March 17, 2026.
📋 Key Facts
- The filing discloses financial results for the full year ended December 31, 2025.
- The announcement was made under Item 2.02 (Results of Operations and Financial Condition).
- The full text of the earnings announcement is contained in Exhibit 99.1.
Abeona Therapeutics issued a press release on March 9, 2026, providing a business update regarding the commercial launch of its product, ZEVASKYN®. The report highlights building momentum for the product's market entry.
📋 Key Facts
- The filing was made under Item 8.01 (Other Events) on March 9, 2026.
- The primary focus is the commercial launch of ZEVASKYN®.
- The company included a press release as Exhibit 99.1 to provide detailed business updates.
- Joseph Vazzano, CFO, signed the report.
Abeona Therapeutics Inc. filed an 8-K to announce the release of its financial results for the quarter ended September 30, 2025.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Signed by Joseph Vazzano, Chief Financial Officer.
Abeona Therapeutics Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results pertain to the period ending June 30, 2025.
- A press release containing the full financial details was issued on August 14, 2025.
Abeona Therapeutics Inc. amended its existing loan agreement with Avenue Venture Opportunities Fund to reduce the interest rate from 13.5% to 11.75%. In exchange, the company issued warrants for up to 16,474 shares of common stock to the lenders.
🚩 Red Flags
- Issuance of equity warrants to lenders (debt-for-equity sweetener) typically indicates the company is seeking to lower cash interest expense at the cost of future dilution.
- The 'change of control' clause provides a mechanism for lenders to receive shares for free if an acquisition occurs at a relatively low premium, which can complicate M&A outcomes.
📋 Key Facts
- Amendment to Loan and Security Agreement dated July 18, 2025.
- Interest rate reduction from 13.5% per annum to a fixed 11.75% per annum.
- Issuance of warrants for up to 16,474 shares of common stock to Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.
- Warrant exercise price set at $6.07 per share.
- Warrants expire on July 18, 2030.
- Includes a 'change of control' provision: if stock price is ≤ 2x the exercise price during a change of control, warrants are exercisable without payment.
Abeona Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million on June 27, 2025. This transaction significantly bolsters the company's liquidity position.
🚩 Red Flags
- None identified in this filing; the transaction appears to be a strategic monetization of an intangible asset rather than a distressed sale.
📋 Key Facts
- Completed sale of Rare Pediatric Disease Priority Review Voucher (PRV) on June 27, 2025.
- Gross proceeds from the asset sale totaled $155 million.
- The PRV was awarded following FDA approval of ZEVASKYN™ (prademagene zamikeracel).
- As of June 30, 2025, total cash, cash equivalents, restricted cash, and short-term investments were approximately $225 million.
- The sale was executed under an agreement dated May 9, 2025.
Abeona Therapeutics Inc. held its annual meeting of stockholders on May 19, 2025. The company successfully elected three Class 3 directors and passed advisory votes regarding executive compensation and the appointment of Deloitte & Touche LLP as independent auditors.
📋 Key Facts
- Annual meeting held virtually on May 19, 2025.
- Mark J. Alvino, Faith L. Charles, and Donald A. Wuchterl elected to Class 3 director seats until the 2028 annual meeting.
- Advisory vote on compensation of named executive officers was approved (25,777,223 votes for).
- Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025, was approved.
Abeona Therapeutics Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal mechanism to incorporate the press release dated May 15, 2025, into the company's SEC reporting.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Filing date: May 15, 2025
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
- Signed by Joseph Vazzano, Chief Financial Officer.
Abeona Therapeutics Inc. entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $155 million in cash. The voucher was awarded by the FDA on April 28, 2025, following the approval of ZEVASKYN™.
🚩 Red Flags
- Asset disposition involves a non-core/regulatory asset rather than operational revenue, though the cash influx is significant for a micro-cap biotech.
📋 Key Facts
- Transaction Value: $155 million payable in cash upon closing.
- Asset Type: Rare Pediatric Disease Priority Review Voucher (PRV).
- Trigger Event: FDA award of PRV on April 28, 2025, following ZEVASKYN™ approval.
- Closing Conditions: Subject to customary conditions including Hart-Scott-Rodino Antitrust Improvements Act waiting periods.
Abeona Therapeutics Inc. announced a conference call and webcast to be held on April 29, 2025, featuring patient videos and presentation slides. This is a routine regulatory disclosure under Regulation FD to provide information to the public via an accompanying presentation.
📋 Key Facts
- Company hosted a conference call and webcast on April 29, 2025, at 8:00 a.m. ET.
- The event included accompanying slides and patient videos.
- Information was furnished under Item 7.01 (Regulation FD Disclosure).
- Exhibit 99.1 contains the webcast presentation.
Abeona Therapeutics Inc. announced that the U.S. FDA has approved ZEVASKYN™ (prademagene zamikeracel), a cell-based gene therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). This represents a significant regulatory milestone and commercialization catalyst for the company.
📋 Key Facts
- FDA approval granted for ZEVASKYN™ (prademagene zamikeracel) on April 29, 2025.
- ZEVASKYN™ is identified as the first and only cell-based gene therapy for RDEB patients.
- The announcement was made via an 8-K filing under Item 8.01 (Other Events).
Abeona Therapeutics Inc. filed an 8-K to announce the release of its financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- The filing is a standard announcement of year-end financial results (FY 2024).
- The report was filed on March 20, 2025.
- Financial results are contained in Exhibit 99.1.
Abeona Therapeutics Inc. announced the results of its special meeting held on December 20, 2024, where stockholders approved an increase in shares reserved for the company's equity incentive plan.
🚩 Red Flags
- Significant increase in share pool (from 3.2M to 8.4M shares) may lead to future dilution for existing shareholders.
📋 Key Facts
- Stockholders approved the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan (Second A&R Plan).
- The number of common shares reserved for issuance under the plan increased from 3,200,000 to 8,400,000 shares.
- Proposal 1 received 20,996,641 votes in favor and 2,876,261 against.
- A quorum was established with 24,567,979 shares (56.35% of outstanding shares) represented at the meeting.
Abeona Therapeutics Inc. filed an 8-K to announce its third quarter 2024 financial results and provide recent corporate updates via a press release.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2024.
- Filing date: November 14, 2024.
- The filing includes Exhibit 99.1 containing the full press release regarding financial results and corporate updates.
Abeona Therapeutics announced that the FDA has accepted its Biologics License Application (BLA) resubmission for Pz-cel, intended to treat Recessive Dystrophic Epidermolysis Bullosa. This represents a significant regulatory milestone in the company's clinical development pipeline.
📋 Key Facts
- FDA has accepted the BLA resubmission for Pz-cel.
- Pz-cel is being developed for the treatment of Recessive Dystrophic Epidermolysis Bullosa.
- The announcement was made via a press release dated November 12, 2024.
Abeona Therapeutics Inc. announced the completion of its Biologics License Application (BLA) resubmission for Pz-cel to the U.S. Food and Drug Administration (FDA). This filing serves as a formal announcement of a key regulatory milestone in the company's clinical pipeline.
📋 Key Facts
- Company completed the BLA resubmission for Pz-cel to the FDA on October 29, 2024.
- The filing is categorized under Item 8.01 (Other Events).
- The announcement was made via a press release dated October 29, 2024.
Abeona Therapeutics Inc. announced the appointment of two new independent directors to its Board: Bernhardt G. Zeiher, MD, and Eric Crombez, MD. Both individuals bring significant pharmaceutical and clinical expertise from companies such as Astellas Pharma, Pfizer, Eli Lilly, and Ultragenyx.
📋 Key Facts
- Bernhardt G. Zeiher, MD, appointed to the Board on August 8, 2024, as a Class 1 director.
- Eric Crombez, MD, appointed to the Board on August 12, 2024, as a Class 2 director.
- Both directors are considered 'independent' under SEC and Nasdaq rules.
- Compensation for each: $50,000 annual cash fee and a one-time $55,000 sign-on equity grant (RSAs) with a one-year vesting period.
- Dr. Zeiher has extensive experience in drug development from Astellas Pharma, Pfizer, and Eli Lilly.
Abeona Therapeutics Inc. released its second quarter 2024 financial results and provided an update regarding a Type A meeting with the FDA concerning their Pz-cel BLA resubmission.
🚩 Red Flags
- Clinical-stage biotech profile typically implies high cash burn and dependency on regulatory milestones.
📋 Key Facts
- Reported Q2 2024 financial results for the period ended June 30, 2024.
- Concluded a Type A meeting with the FDA to align on the upcoming Pz-cel Biologics License Application (BLA) resubmission.
- Filed via Item 2.02 (Results of Operations and Financial Condition).
Abeona Therapeutics Inc. announced an amendment and restatement of its bylaws approved by the Board on July 5, 2024. The change specifically modifies notice requirements for calling special meetings of the Board.
📋 Key Facts
- The Board of Directors approved the 'Second A&R Bylaws' on July 5, 2024.
- Amendment allows special meetings of the Board to be called with at least 24 hours' notice via personal, telephone, or electronic means.
- The Second A&R Bylaws became effective on July 8, 2024.
Abeona Therapeutics Inc. filed an 8-K to announce its first quarter 2024 financial results and recent corporate progress via a press release.
📋 Key Facts
- Report covers the fiscal quarter ended March 31, 2024.
- The filing includes Exhibit 99.1 containing the full press release of financial results.
- Filed on May 15, 2024.
Abeona Therapeutics Inc. entered into an underwriting agreement to conduct a $75 million underwritten offering consisting of common stock and pre-funded warrants. The net proceeds are expected to be approximately $70.2 million, intended to bolster the company's liquidity.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 12 million new shares and significant warrant coverage.
📋 Key Facts
- Offering size: 12,285,056 shares of common stock and 6,142,656 pre-funded warrants.
- Pricing: $4.07 per share; Pre-Funded Warrants priced at $4.0699 (representing a $0.0001 exercise price).
- Estimated net proceeds: Approximately $70.2 million after commissions and expenses.
- Underwriter: Stifel, Nicolaus & Company, Incorporated.
- Expected closing date: On or about May 7, 2024.
- Warrant restriction: Holders cannot exercise warrants if it results in beneficial ownership exceeding 4.99% (or up to 9.99% by election).
Abeona Therapeutics announced the suspension and termination of its 'At-the-Market' (ATM) prospectus supplement, effectively halting the sale of up to $106 million in common shares under that specific agreement. The company also provided preliminary cash position updates for the quarter ended March 31, 2024.
🚩 Red Flags
- Suspension of ATM program: The termination of an ATM program can sometimes indicate a desire to avoid further dilution or, conversely, an inability to access capital through that specific mechanism without a new registration.
- Preliminary financial data: The $62.7 million cash figure is unaudited and subject to change.
📋 Key Facts
- As of March 31, 2024, estimated cash, cash equivalents, restricted cash, and short-term investments total approximately $62.7 million.
- The company terminated the prospectus supplement dated June 7, 2023, which related to an ATM program for up to $106,000,000 of common shares.
- The underlying Sales Agreement dated August 17, 2018, remains in full force and effect.
- No further sales will occur under the terminated supplement until a new registration statement or prospectus is filed.
Abeona Therapeutics Inc. reported the results of its annual meeting of stockholders held on April 24, 2024. Key outcomes included the election of two new directors and stockholder approval for an expanded equity incentive plan.
📋 Key Facts
- Stockholders approved the Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan (A&R Plan).
- The A&R Plan increases the number of common shares reserved for issuance from 1,700,000 to 3,200,000.
- Leila Alland and Vishwas Seshadri were elected as Class 2 directors until the 2027 annual meeting.
- Stockholders approved an advisory vote on compensation for named executive officers.
- Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2024.
Abeona Therapeutics Inc. filed an 8-K to announce a regulatory update regarding its product candidate, Pz-cel. The filing serves primarily as a vehicle to incorporate a press release into the company's official SEC record.
📋 Key Facts
- The filing was made on April 22, 2024.
- The primary content is a regulatory update concerning 'Pz-cel'.
- The announcement is contained within Exhibit 99.1.
Abeona Therapeutics Inc. filed an 8-K to announce the release of its financial results for the fiscal year ended December 31, 2023.
📋 Key Facts
- The filing relates to the issuance of a press release regarding annual financial results for the period ending Dec 31, 2023.
- The report was filed on March 18, 2024.
- Financial results are contained in Exhibit 99.1.
Abeona Therapeutics entered into a senior secured term loan agreement with Avenue Venture Opportunities Fund, L.P. for up to $50 million in total facility size. The deal includes an immediate $20 million tranche and features high interest rates and significant warrant issuances.
🚩 Red Flags
- High interest rate (floor of 13.50% p.a.) suggests high perceived risk by lenders.
- Significant dilution potential via warrants ($2.4M total value) and a conversion right for $3 million of principal into common stock at 120% of the warrant exercise price.
- Restrictive financial covenant requiring maintenance of $5 million in unrestricted cash.
- Prepayment penalties including a final payment fee of 5.00% on funded tranches.
📋 Key Facts
- Total aggregate principal amount of loans: up to $50 million.
- Tranche 1: $20 million advanced on January 8, 2024.
- Tranche 2: Up to $10 million contingent upon FDA approval of pz-cel and issuance of a Priority Review Voucher (expected June 30 - Sept 30, 2024).
- Discretionary Tranche: Up to $20 million at Lender discretion between March 31, 2025, and March 31, 2026.
- Interest Rate: Greater of prime + 5.00% or 13.50% per annum.
- Maturity Date: July 1, 2027.
- Security: Pledge of substantially all of the Company's assets.
- Financial Covenant: Must maintain $5 million in unrestricted cash at all times.
- Warrants issued to Avenue and Avenue 2 for a total of $2.4 million worth of common stock, with an exercise price of the lesser of $4.75 or the next equity financing price.